Tag Archive for: ICG

Weekly wrap-up: $100m Series B financing for a bivalent vaccine, to new clinical data from a cutting-edge antibody-drug conjugate…

Vicebio Announces $100 Million Series B Financing and Initiation of Phase 1 Clinical Study of RSV/hMPV Bivalent Vaccine  Vicebio Ltd, a biopharmaceutical company developing novel vaccines against life-threatening respiratory viral infections, on Monday announced a $100 million Series B financing  led by TCGX  with investment from Goldman Sachs Alternatives, Avoro Ventures, venBio,  and participation from UniQuest and founding investor Medicxi.  London-based Vicebio said funding […]

Optimum’s clients build momentum in March

Optimum’s clients continued to gain momentum in March, starting things off on Monday with a substantial financing agreement for Heidelberg Pharma, with HealthCare Royalty for up to $115 million. On Wednesday, Heidelberg followed this with the announcement that it is to present first efficacy data from a Phase 1 clinical trial with ATAC candidate HDP-101. […]

Insights from Optimum’s 15th Annual Healthcare Investor Conference 2023

Optimum Strategic Communications celebrated its 15th Annual Healthcare Investor Conference – marking its crystal anniversary – and what a sparkler it was! Optimism, preparation, and resilience, these were the key takeaways from our wonderful speakers on Wednesday 11 October at the Wellcome Trust. Check out our panel summaries below to learn more or to rediscover […]